NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for its intranasal drug NEO100 in patients with recurrent IDH1-mutant high-grade ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE